Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Bosch

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancerJoan Climent, Jesus Perez-Losada, David A Quigley, et al.
Translational Oncology|June 6, 2022
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancerChristopher Godina, Vineesh Indira Chandran, Magdalena Barbachowska, et al.
Breast (Edinburgh, Scotland)|August 6, 2011
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?Jose Alejandro Pérez-Fidalgo, Paola Pimentel, Antonio Caballero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast CancerYalai Bai, Kimberly Cole, Sandra Martinez-Morilla, et al.
Oncology|November 29, 2002
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Jose Manuel Aramendia, et al.
Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Breast Cancer Research : BCR|February 19, 2021
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancerKamila Kaminska, Nina Akrap, Johan Staaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyCristina Saura, Johanna Bendell, Guy Jerusalem, et al.
BMC Cancer|July 23, 2014
MicroRNA profile in very young women with breast cancerMaria Peña-Chilet, Maria T Martínez, Jose A Pérez-Fidalgo, et al.
Nature Communications|March 5, 2025
Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancerLennart Hohmann, Kristin Sigurjonsdottir, Ana Bosch Campos, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancerJoan Climent, Jesus Perez-Losada, David A Quigley, et al.
Translational Oncology|June 6, 2022
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancerChristopher Godina, Vineesh Indira Chandran, Magdalena Barbachowska, et al.
Breast (Edinburgh, Scotland)|August 6, 2011
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?Jose Alejandro Pérez-Fidalgo, Paola Pimentel, Antonio Caballero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast CancerYalai Bai, Kimberly Cole, Sandra Martinez-Morilla, et al.
Oncology|November 29, 2002
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Jose Manuel Aramendia, et al.
Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Breast Cancer Research : BCR|February 19, 2021
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancerKamila Kaminska, Nina Akrap, Johan Staaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyCristina Saura, Johanna Bendell, Guy Jerusalem, et al.
BMC Cancer|July 23, 2014
MicroRNA profile in very young women with breast cancerMaria Peña-Chilet, Maria T Martínez, Jose A Pérez-Fidalgo, et al.
Nature Communications|March 5, 2025
Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancerLennart Hohmann, Kristin Sigurjonsdottir, Ana Bosch Campos, et al.
Pageof 5